.jpg)
.png)
Last Updated: Monday, 11-Feb-2019 20:45:00 EST
Sanofi and Regeneron announced on Monday, Feb. 11 alirocumab will be made available at a reduced list price to help lower patient out-of-pocket costs and improve access.
Last Updated: Wednesday, 16-Jan-2019 18:30:00 EST
The NLA has released its clinician tear sheet on the 2018 Guideline on the Management of Blood Cholesterol.
The tear sheet is an important resource for physicians to quickly and easily reference key points from the 2018 Guideline at a glance. It can be printed or shared electronically for reference at physician practices in addition to being shared among colleagues.
Check back later for more NLA clinical resources and tools related to the 2018 Guideline.
Last Updated: Tuesday, 18-Dec-2018 19:00:00 EST
 |
 |
Last Updated: Saturday, 10-Nov-2018 23:00:00 EST
Nov. 10, 2018
CHICAGO ‒ The REDUCE-IT cardiovascular outcomes trial results, announced today at the American Heart Association Scientific Sessions in Chicago, met its primary composite endpoint and revealed a reduction in major adverse cardiovascular events (MACE) of 25%.
Download the manuscript online now.
Last Updated: Friday, 09-Nov-2018 13:30:00 EST
Nov. 10, 2018
NLA among 12 organizations to co-author, endorse key document for reducing risk of atherosclerotic cardiovascular disease
Last Updated: Thursday, 25-Oct-2018 14:30:00 EDT
Oct. 25, 2018
Amgen announced on Wednesday, Oct. 24 it is making evolocumab available at a reduced list price in an effort to improve affordability and access for patients.
The announcement represents positive news for patients at risk for cardiovascular events.
Key outcomes from Amgen’s FOURIER trial, revealed in March 2017, revealed evolocumab significantly reduced the risk of cardiovascular events and were supported by long-term safety data.
The Foundation of the NLA has seen great progress over the past several months. At our summer board of directors meeting, the board voted unanimously to add seven new at-large board members: Joyce L. Ross, MSN, CRNP, CLS, FNLA from the University of Pennsylvania Health System, Lori A. Alexander, MSHS, RD, CCRC, CLS, FNLA from the Jacksonville Center for Clinical Research, Robert A. Wild, MD, MPH, PhD, FNLA, FASPC from Oklahoma University Health Sciences Center, Don P.
Article By:
ANNE C. GOLDBERG, MD, FNLA
President, Foundation of the National Lipid Association
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology
Q: Your work in discovering the role of cholesterol crystals on cardiovascular attacks is renowned. Could you tell us about the impact that this made on how we view and treat plaque?
Article By:
GEORGE S. ABELA, MD, MSc, MBA
Professor and Chief, Division of Cardiology
Michigan State University
East Lansing, MI
The inaugural Donald Fredrickson Conference on Familial Lipoprotein Disorders was convened on Sunday, April 29, 2018 at the end of the National Lipid Association Annual Scientific Sessions in Las Vegas. The meeting was chaired by Dr. Virgil Brown.
Article By:
P. BARTON DUELL, MD, FNLA
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR
W. VIRGIL BROWN, MD, FNLA
Charles Howard Candler Professor of Internal Medicine Emeritus
School of Medicine
Emory University
Atlanta, GA
Diplomate, American Board of Clinical Lipidology
The Midwest Lipid Association is 510 members strong and represents Indiana, Illinois, Wisconsin, Michigan, Ohio, Kansas, Iowa, Missouri, North Dakota, South Dakota, Minnesota and Nebraska. We are pleased to have David R. Neff, DO, FNLA, serving as our President this year. We have an active and diverse group and Sanford A. Carimi, MD, FNLA, our Immediate Past President, took time at our February meeting to acknowledge the great MWLA representation on national level projects. Ann M.
Article By:
SARAH J. HALLBERG, DO, MS, FNLA
President-Elect, Midwest Lipid Association
Medical Director
Medically Supervised Weight Loss Program
Indiana University Health Arnett
Indiana University School of Medicine
Lafayette, IN
Diplomate, American Board of Clinical Lipidology